X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to leverage Omega's proprietary platform technology to develop an epigenomic controller designed to enhance metabolic activity as a part of a potential new treatment approach for obesity management.
Lead Product(s): Undisclosed
Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Novo Nordisk
Deal Size: $532.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 04, 2024
Details:
OTX-2002 is an mRNA therapeutic delivered via lipid nanoparticles (LNPs) designed to downregulate MYC expression pre-transcriptionally through epigenetic modulation while potentially overcoming MYC autoregulation.
Lead Product(s): OTX-2002,Undisclosed
Therapeutic Area: Oncology Product Name: OTX-2002
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2023
Details:
Under the agreement, Omega will evaluate OTX-2002 in development for the treatment of MYC-driven hepatocellular carcinoma (HCC), in combination with Roche’s anti-PD-L1 therapy, atezolizumab, as part of Omega’s Phase 1/2 MYCHELANGELO™ I clinical trial.
Lead Product(s): OTX-2002,Atezolizumab
Therapeutic Area: Oncology Product Name: OTX-2002
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 30, 2023
Details:
OTX-2002 is a first-in-class Omega Epigenomic Controller in development for the treatment of HCC. OTX-2002 is an mRNA therapeutic delivered via LNPs and is designed to downregulate MYC expression pre-transcriptionally through epigenetic modulation.
Lead Product(s): OTX-2002,Undisclosed
Therapeutic Area: Oncology Product Name: OTX-2002
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 23, 2023
Details:
OTX-2002, is designed to downregulate MYC expression pre-transcriptionally through epigenetic modulation (a master transcription factor that regulates cell proliferation, differentiation and apoptosis). It is being developed for hepatocellular carcinoma.
Lead Product(s): OTX-2002,Undisclosed
Therapeutic Area: Oncology Product Name: OTX-2002
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2023
Details:
OTX-2002 is first-in-class Omega Epigenomic Controller for treatment of HCC, is an mRNA therapeutic delivered via LNP and is designed to downregulate MYC expression pre-transcriptionally through epigenetic modulation while potentially overcoming MYC autoregulation.
Lead Product(s): OTX-2002,Undisclosed
Therapeutic Area: Oncology Product Name: OTX-2002
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2022
Details:
OTX-2002, a novel epigenomic controller, is an mRNA therapeutic designed to downregulate MYC expression pre-transcriptionally through epigenetic modulation while potentially overcoming MYC autoregulation.
Lead Product(s): OTX-2002,Undisclosed
Therapeutic Area: Oncology Product Name: OTX-2002
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2022
Details:
OTX-2101 is a first-in-class Omega Epigenomic Controller™ in development for the treatment of non-small cell lung cancer (NSCLC). OTX-2101 effectively reduced tumor growth in vivo and was well tolerated in murine xenograft models, further supporting its clinical potential.
Lead Product(s): OTX-2101
Therapeutic Area: Oncology Product Name: OTX-2101
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2022
Details:
OTX-2002 is an mRNA therapeutic delivered via lipid nanoparticles (LNPs) and is designed to downregulate MYC expression pre-transcriptionally through epigenetic modulation while potentially overcoming MYC autoregulation.
Lead Product(s): OTX-2002
Therapeutic Area: Oncology Product Name: OTX-2002
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 14, 2022
Details:
OTX-2002 is Omega Epigenomic Controller™ in development for treatment of HCC, is an mRNA therapeutic delivered via LNPs and is designed to downregulate c-MYC expression pre-transcriptionally through epigenetic modulation potentially overcoming MYC autoregulation.
Lead Product(s): OTX-2002
Therapeutic Area: Oncology Product Name: OTX-2002
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
